Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)

NCT03719690 is registered in ClinicalTrials.gov with Kura Oncology, Inc. as lead sponsor.

NCT NCT03719690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03719690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)
Lead sponsor
Kura Oncology, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 15, 2019
Completion date
May 2, 2023
Enrollment
296 (actual)
Sites
102

Conditions

As the registry lists them; a condition with its own page is linked.

hnscc, hras gene mutation